Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Down 6.13%
As of Friday, July 31, Aardvark Therapeutics, Inc.’s AARD share price has dipped by 6.13%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Commentary & Analysis
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Up 8.18%
As of Thursday, July 30, Aardvark Therapeutics, Inc.’s AARD share price has surged by 8.18%, which has investors questioning if this is right time to sell.Michael Rose
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Up 14.10%
As of Thursday, July 30, Aardvark Therapeutics, Inc.’s AARD share price has surged by 14.10%, which has investors questioning if this is right time to sell.Omar Beirat
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Down 5.37%
As of Wednesday, July 29, Aardvark Therapeutics, Inc.’s AARD share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Up 7.04%
As of Monday, July 27, Aardvark Therapeutics, Inc.’s AARD share price has surged by 7.04%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | AARD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $139.6 | $569.9 | 24% |
|
| Shares Out (Mil) | 21.8 | 44.8 | 32% |
|
| Institutional Ownership | 58.7% | 84.6% | 38% |
|
| Float (Mil) | 10.9 | 45.1 | 21% |
|
| Beta | na | 0.67 | na |
|
| Avg Daily Volume (000s) | 153 | 294 | 41% |
|
| Price Change (52-week) |
(50.7%) | 65.2% | 15% |
|
| Growth | AARD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (2.0%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 9 | 9 | |
| Current EPS | ($0.881) | ($3.668) | ($3.098) | |
| Month Ago EPS | ($0.869) | ($3.651) | ($3.238) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.876) | ($3.421) | ($3.468) | |
| Year/Year Chg | (11.0%) | 25.0% | 4.9% | |
| Financials | AARD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $230 | na |
|
| Net Income (TTM) (Mil) | ($70) | ($11) | 14% |
|
| EPS (TTM) | ($3.208) | ($0.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($62) | ($6) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $36 | $4 | 68% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | $28 | $493 | 12% |
|
| Valuation | AARD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.60 | 2.89 | 42% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AARD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | (0.2%) | na |
|
| ROA | (54.7%) | (25.5%) | 11% |
|
| ROE | (58.8%) | (21.4%) | 14% |
|
| Liabilities to Assets | 11.8% | 35.5% | 7% |
|
| F-Score | 1 | 3 | 1% |
|
Aardvark Therapeutics, Inc. did not pass any screens on 7/30/2026.
